Numab Therapeutics AG. (3/9/20). "Press Release: Numab Therapeutics Closes Series B Financing at CHF 22M to Advance Portfolio of Novel Multi-specific Antibodies in Immuno-Oncology". Wädenswil (Zurich).

	Organisation	Numab Therapeutics AG
	Group	Numab (Group)
	Product	MATCH™ platform (Numab)
	Product 2	venture capital
	Index term	Numab–SEVERAL: investment, 201912–202003 financing round Series B CHF22m incl €15m from new investor 3SBio/Sunhine Guojian
	Person	Urech, David (Numab 201910 CEO + Co-Founder before Esbatech 2004–2010)
	Person 2	Vasella, Daniel (Novartis CEO 199612–201001 after 1/10 continues as Chairman)

Numab Therapeutics announced today the closing of its Series B financing round at a total volume of CHF 22M (approximately USD 22.6M). New investors in this round included 3SBio/Sunshine Guojian, Mitsubishi UFJ Capital Co., Ltd. and Eisai Co., Ltd. as well as Numab’s board member Dr. Daniel Vasella. Existing shareholders that participated in Numab’s Series A round also contributed to today’s financing. With the financing secured, Numab plans to further broaden its proprietary pipeline and accelerate the development for a number of programs towards the clinic. The company also plans to initiate a clinical trial for its lead oncology program ND021 during the course of 2020.

Mitsubishi UFJ Capital is one of Asia’s leading venture capital firm focusing on life science, information and communications technology and high technology investments. Numab and Eisai entered into a global research and option agreement to discover and develop a portfolio of multi-specific antibody immunotherapies for cancer in October 2019. In December 2019, Numab added a regional alliance with 3SBio’s subsidiary Sunshine Guojian Pharmaceutical Co., Ltd. to its growing roster of pharmaceutical partnerships.

“We are very pleased to have attracted a renowned institutional investor in Mitsubishi UFJ Capital to the Numab story and likewise appreciate the additional display of confidence in our platform and pipeline strategy by our partners as well as existing Series A investors and our board member Daniel Vasella,” commented Dr. David Urech, Chief Executive Officer of Numab Therapeutics.

Multi-specific antibodies have the potential to unlock entirely novel modes-of-action aiming at superior benefit-to-risk profiles relative to conventional cancer immune therapies. Numab’s proprietary MATCH™ technology platform represents one of the most versatile and flexible sources for multi-specific antibodies. MATCH™ molecules can incorporate up to six binding specificities in true plug-and-play fashion. The individual antibody Fv building blocks are designed for maximum stability and developability.

About Numab Therapeutics

Numab Therapeutics is an oncology-focused biopharmaceutical company based in Zurich-area, Switzerland. At Numab, we are writing the next chapter in cancer immunotherapy by creating multispecific antibodies that enable the pursuit of novel therapeutic strategies. With our proprietary MATCH™ technology platform we are fueling a new wave of multi-specific drug candidates engineered with versatility and developability in mind. Our lead product was designed to balance potent anti-tumor immunity with a desirable safety profile by targeting 4-1BB, PD-L1 and Human Serum Albumin simultaneously. We believe meeting the highest quality standards in every step of the drug design process matters and will result in better patient outcomes. For further information, visit www.numab.com.

Contacts:

For Numab Therapeutics
David Urech
Chief Executive Officer
[email protected]

For media
MacDougall
Sara Michelmore or Caroline Rufo, PhD.
+1 781-235-3060
[email protected]

Record changed: 2023-06-05